• Bristol Myers Squibb secured FDA acceptance of its NDA for mezigdomide with carfilzomib, dexamethasone in relapsed or refractory multiple myeloma.
• The FDA set a PDUFA target action date of May 13, 2027.
• Filing backed by Phase 3 SUCCESSOR-2 data showing median PFS 18.0 months vs. 8.3 months; HR 0.48; p<0.0001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130659BIZWIRE_USPR_____20260713_BW597234) on July 13, 2026, and is solely responsible for the information contained therein.